JCR Pharma achieved sales of 40.3 billion yen (up 21.9% YoY) for the fiscal year ending March 2026, and recovered to a net profit of 2.1 billion yen. Increased R&D expenses and progress in new drug development contributed to the performance. The company anticipates continued sales growth and proactive investments in the next period to aim for long-term growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4552-20260623-04.pdf","jir_short_summary":"JCR Pharma achieved sales of 40.3 billion yen (up 21.9% YoY) for the fiscal year ending March 2026, and recovered to a net profit of 2.1 billion yen. Increased R&D expenses and progress in new drug development contributed to the performance. The company anticipates continued sales growth and proactive investments in the next period to aim for long-term growth.","jir_summary":"### Overview of Financial Performance\nJCR Pharma recorded net sales of 40.3 billion yen (up 21.9% YoY) for the fiscal year ending March 2026, and turned profitable with a net income of 2.1 billion yen. Contributing factors include strong sales of the enzyme therapy drug \"Izarga\u00ae\" for mucopolysaccharidosis and progress in new drug development. R&D expenses increased, and the company plans to continue expanding sales and making active investments to achieve long-term growth.\n\n### Future Outlook and Shareholder Returns\nFor the next fiscal year ending March 2027, sales are expected to reach 45.7 billion yen (up 13.3% YoY), with R&D expenses increasing to 19.3 billion yen. Operating profit is forecasted at 1.1 billion yen, and the company plans to maintain a dividend of 20 yen. By pursuing long-term research investments and new drug development, the company aims for sustainable growth.","jir_financial_highlights":"Net Sales: 40,319 million yen (Up 21.9% YoY)\nNet Income Attributable to Owners of Parent: 2,178 million yen (Turned positive from a loss of 4,460 million yen in the previous year)\nR&D Expenses: 16.761 billion yen (Increased by 1.33 billion yen YoY)","jir_category":"","jir_hashtags":"#JCRPharma, #Earnings, #JapanStocks","jir_key_figures":"Net Sales: 40,319 million yen (up 21.9% YoY)\nNet Income Attributable to Owners of Parent: 2,178 million yen (turned positive)\nR&D Expenses: 16.761 billion yen (up 1.33 billion yen YoY)","jir_meta_title":"\u3010JCR Pharma\u30112026 Earnings | Revenue increased by 40.3 billion yen, net profit 2.1 billion yen","jir_meta_description":"JCR Pharma achieved sales of 40.3 billion yen (up 21.9% YoY) and recovered to a net profit of 2.1 billion yen for the fiscal year ending March 2026. The company plans to continue expanding sales and investing in R&D for sustainable growth.","jir_og_title":"\u3010JCR Pharma\u30112026 Earnings | Revenue increased by 40.3 billion yen, net profit 2.1 billion yen","jir_og_description":"JCR Pharma posted sales of 40.3 billion yen and net income of 2.1 billion yen for the fiscal year ending March 2026, turning profitable. The company will continue to pursue sales expansion and R&D investments for long-term growth.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-67742","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n